Bob Ingram is in no danger of getting bored.

On May 18, the retired CEO of Glaxo Wellcome plans to join the board of PPD, the Wilmington-based pharmaceutical research company with a large operation in the Triangle. It's just the latest role for one of this region's busiest and most experienced corporate leaders.

Ingram, 68, is also a general partner with Durham-based investment firm Hatteras Venture Partners. In January, he became chairman of Elan Corp., an Irish biotechnology firm.

He's also on the boards of other public companies Allergan, Cree, Edwards Lifesciences and Valeant Pharmaceuticals. And he serves as a strategic advisor to GlaxoSmithKline CEO Andrew Witty.

One of the Triangle's most experienced pharmaceutical industry executives will join Elan Corp. as chairman of the Irish biotechnology company's board.

Robert Ingram has joined Elan's board and will replace Kyran McLaughlin as chairman on Jan. 26, the company announced this morning.

"I look forward to working with the Board and the management team to deliver long term benefits to science, patients and shareholders," Ingram said in a prepared statement.

Ingram was CEO of Glaxo and later vice chairman of GlaxoSmithKline. Since January, Ingram also has worked as an advisor to GSK Chief Executive Andrew Witty. The British pharmaceutical giant has its North American headquarters in Research Triangle Park.

Ingram, who turns 68 today, was traveling and didn't return calls seeking comment.